Search results

  • Full text

  • Document type

    • Publication year

  • Organisation

Results: 66
Number of items: 66
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 1 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673812.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 13 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673803.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P., & Van Kampen, A. H. C. (2020). Additional file 8 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673833.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 10 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673794.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 2 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673815.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 14 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673806.v1
  • Soleimani Dodaran, M., Borgoni, S., Sofyall, E., Verschure, P. J., Wiemann, S., Moerland, P. D., & Van Kampen, A. H. C. (2020). Additional file 3 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer [Data set]. Figshare. https://doi.org/10.6084/m9.figshare.12673818.v1
  • Mandemaker, I. K., Zhou, D., Bruens, S. T., Dekkers, D. H., Verschure, P. J., Edupuganti, R. R., Meshorer, E., Demmers, J. A. A., & Marteijn, J. A. (2020). Histone H1 eviction by the histone chaperone SET reduces cell survival following DNA damage. Journal of Cell Science, 133, Article jcs235473. https://doi.org/10.1242/jcs.235473
  • Open Access
    Borgoni, S., Sofyali, E., Soleimani, M., Wilhelm, H., Müller-Decker, K., Will, R., Noronha, A., Beumers, L., Verschure, P. J., Yarden, Y., Magnani, L., van Kampen, A. H. C., Moerland, P. D., & Wiemann, S. (2020). Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer. Cancers, 12(10), Article 2918. https://doi.org/10.3390/cancers12102918
  • Open Access
    Gjaltema, R. A. F., Goubert, D., Huisman, C., García Tobilla, C. P., Koncz, M., Jellema, P. G., Wu, D., Brouwer, U., Kiss, A., Verschure, P. J., Bank, R. A., & Rots, M. G. (2020). KRAB-Induced Heterochromatin Effectively Silences PLOD2 Gene Expression in Somatic Cells and is Resilient to TGFβ1 Activation. International Journal of Molecular Sciences, 21(10), Article 3634. https://doi.org/10.3390/ijms21103634
Page 2 of 7